Pacific Biosciences of California (PACB) Q2 FY26 earnings call

Pacific Biosciences reported a mixed Q2 FY26, marked by a CEO transition and the full commercial launch of its Spark Next chemistry, which is driving multi-system Revio orders and clinical adoption. Despite strong customer enthusiasm for Spark Next and significant scientific validation for HiFi sequencing, the company lowered its full-year revenue and gross margin guidance, pushing cash flow breakeven to 2028, citing Spark Next transition dynamics, elevated compute costs, and funding headwinds in key regions. The new leadership is focused on scaling growth, sharpening execution, and optimizing